38 results about "Collagen Type III" patented technology

The invention discloses a scar repair material which is prepared by the following method: dissolving 0.5-5 parts by weight of water-soluble chitosan or chitosan the deacetylation degree of which is 75-97% into 10-100 parts by weight of water or an acetic acid aqueous solution the mass concentration of which is 1-5% while stirring; adding 1-3 parts by weight of polyoxyethylene Sorbitan lauric acid monoester which has emulsifying action and 5-10 parts by weight of humectant glycerol to obtain a transparent gelatinous solution; adding 20-90 parts by weight of polydimethylsiloxane into the gelatinous solution under homogeneity; and evenly mixing to obtain the scar repair material. The scar repair material disclosed in the invention can actively and passively moisturize skin, has the efficacy on actively resisting and inhibiting bacteria, has the action on quickening the healing of skin wound surface, has better repair and protection actions on tiny flaws and infection on the scar surface as being used on the scar surface, and can inhibit the secretion of collagen type I in cheloid skin so as to lower the ratio of collagen type I/collagen type III.

The invention belongs to the technical field of biological material of tissue engineering. The invention discloses a cell culture substrate, a preparation method thereof, and an application thereof. According to the invention, umbilical cord fibroblast cell self-secretion substrate is adopted; and through decellularization treatment and drying and sterilization, a natural tissue engineering material is obtained. The material comprises collagen type I, collagen type III, fibronectin, laminin, decorin, and the like, and can be used in in-vitro amplification of target mesenchymal stem cells. With the cell culture substrate provided by the invention, mesenchymal stem cell in-vitro amplification efficiency can be substantially improved, special immune phenotype of stem cells can be maintained, and stem cell active oxygen content can be substantially reduced. Also, raw material source is wide, and no ethic and moral problem is caused.

The invention discloses a method for preparing a medical III type collagen, which is characterized by comprising the following steps of: pre-treating fresh newborn kip as a raw material and then extracting a mixture of I type and II type collagens by using a pepsin degradation limiting method and a salting out method; dissolving the mixture with 1.5 mol/L NaCl and 0.05mol/L Tris buffer solution the pH value of which is 7.5 for 2-5 times to remove most of I type collagen; heating the mixture with 2-6mol/L guanidine hydrochloride and 0.05mol/L Tris-HCl buffer solution the pH value of which is 7.5 in a water bath with the temperature of 45-95 DEG C for 30-60 minutes to modify the collagens; reducing the temperature and the concentration of the guanidine hydrochloride; renaturing the II type collagen after 2-6 hours; and centrifuging the mixture at high speed to obtain a III type collagen.

The invention discloses a method for simultaneously labelling collagen type IV, macrophage and neovascularisation of tumors. The method comprises the following steps: 1. immobilizing tissue sections on a plus microscope slide processed by polylysine; 2. dewaxing the tissue sections in dimethylbenzene; 3. carrying out antigen retrieval; 4. washing the sections; 5. carrying out confining; 6. addingprimary antibodies; 7. washing the sections; 8. carrying out confining in the same way as the step 5; 9. using the fragment antigen-binding F(ab')2-QDs525 of goat anti-mouse immunoglobulin G labelledby quantum dot QDs525, the fragment antigen-binding F(ab')2-QDs585 of goat anti-rabbit immunoglobulin G labelled by quantum dot QDs585 and the fragment antigen-binding F(ab')2-QDs655 of rabbit anti-goat immunoglobulin G labelled by quantum dot QDs655 as secondary antibodies and dropwise adding the mixture after removing the confining liquid; 10. washing the sections; and 11. sealing the sections:preparing buffered glycerol with glycerol and 10ml of tris buffered saline (TBS) and storing the sections after sealing the sections with the buffered glycerol. The method is used for efficiently, accurately, rapidly and simultaneously detecting various components in tumor tissue microenvironment.

The invention belongs to the field of cosmetics and particularly relates to an anti-aging composition and preparation and application thereof. The anti-aging composition is prepared from the following ingredients in parts by weight: 1 to 3 parts of hydrolyzed pearl powder, 1 to 3 parts of dioscorea villosa root extract, 0.5 to 2 parts of acetyl hexapeptide-8, 0.5 to 2 parts of acetyl octapeptide-3 and 0.5 to 2 parts of nonapeptide-1. Experiments prove that the anti-aging composition disclosed by the invention has an extremely obvious removing effect on quiescent wrinkles, dynamic wrinkles and posture extrusion wrinkles, meanwhile can obviously promote multiplication of human skin fibroblast, extremely obviously promotes synthesis of I and III type collagen and extremely obviously inhibits expression of MMP1 and MMP3.

The present invention relates to multimicrolamellar membranes of collagen of several types and structures (e.g. collagen type I, type II, type III, etc.), of only one type or two types in association, but more particularly of type I and type II collagen and/or of their mixture. The multimolecular arrangement is obtained by preparing the membrane in several steps involving the sequential addition of collagen gel layers. Membranes look thin, with a variable rough surface depending on the type of collagen used. Such membranes show a parallel horizontal lamellar microstructure and they can be soaked with different fluids, act as three-dimensional scaffold for cultured cells and are apt to be infiltrated and colonized by cells in vivo, therefore working as support suitable for direct, guided tissue regeneration. Moreover, the present invention relates to the preparation of said membranes from collagen gels and to the optimization of the preparation of collagen gel from tissues.

The invention provides a primary culture method of rheumatoid arthritis synovial fibroblasts. The method comprises the steps of sufficiently crushing pretreated synovial tissue; adding type-III collagenase and type-II collagenase into the synovial tissue and conducting blowing and beating; after culture digestion, scattering the synovial tissue into single cells; after filtering, centrifuging a filtrate, taking a substratum precipitate, and inoculating the substratum precipitate into a DMEM high-glucose culture medium for adherent culture; adopting a natural purification method and a repeatedadherent method for purifying the cells to obtain the rheumatoid arthritis synovial fibroblasts. By means of the culture method, about 1,010 RASFs can be obtained within 30 days, the cell yield is greatly increased, multiple experiment demands can be met, and therefore, the primary culture method is a quick and effective primary RASFS isolation culture method. In the meanwhile, compared with synovial cell lines of in-vitro construction lines, the RASFs obtained through primary culture have higher study value, and have a good practical application prospect.

The invention discloses a method for constructing a composite scaffold of pig-derived collagen membrane-autologous chondrocytes. The specific steps are as follows: take the patient's articular cartilage, shake and clean it; cut the cartilage tissue into pieces; obtain cell suspension; precipitate as chondrocytes; Dried the porcine type Ⅰ/Ⅲ collagen membrane, placed it in a sterile plastic plate, slowly dripped the cell suspension on the rough surface of the prepared porcine type Ⅰ/Ⅲ collagen membrane with a plastic sleeve until the collagen membrane reached Wet and saturated state; wait for 10-15 minutes after the collagen membrane adsorbs the cells. The invention has the advantages of good therapeutic effect and the like.

The invention relates to a GLP-1 analogue-COL3A1 fusion protein. Specifically, the fusion protein comprises the glucagon-like peptide 1 analog and a human type III collagen alpha1 chain fusion protein, and the fusion protein has the hypoglycemic effect of the glucagon-like peptide 1 and has an extended half-life in vivo.

Provided herein are biocompatible and/or biodegradable hydrogel compositions comprising native collagen and chondroitin sulfate, the collagen and chondroitin sulfate being chemically cross-linked thereby forming a matrix. The native collagen may comprise recombinant human collagen type I (rHCI), recombinant human collagen type III (rHCIII), or a combination thereof, for example. Methods and uses thereof for regeneration or repair of tissue, improvement of tissue function, mechanical stabilization of tissue, prevention of tissue damage, or prevention of tissue loss of function are described, particularly with respect to cardiac tissue and myocardial infarction events.

The invention relates to a biochemical marker for CVD risk evaluation and a method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein of an atherosclerotic plaque such as lumican, versican, perlecan, decorin, biglycan, collagen type III, CRP, ApoE, or elastin, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.

The invention discloses a preparation method for a collagen membrane inoculated with autologous mesenchymal stem cells. The preparation method comprises the following concrete steps: carrying out uniform mixing so as to obtain a marrow suspension; preparing autologous serum; adding the marrow suspension into a centrifuge tube containing a cell separating medium and carrying out gradient centrifugation to obtain a sediment which is target cells; adding the target cells into 15 ml of a DMEM high-glucose medium containing FGF-2, the autologous serum and gentamycin, carrying out culturing in an incubator and replacing the DMEM high-glucose medium once every three days; after cell culture for 3 to 4 weeks, carrying out passage three times; subjecting cells to resuspension with normal saline; slowly adding the cell suspension onto the rough surface of a prepared pig-sourced I/III type collagen membrane with a plastic sleeve drop by drop; and allowing the collagen membrane to adsorb cells for 10 to 15 min so as to obtain the collagen membrane inoculated with the autologous mesenchymal stem cells. The collagen membrane inoculated with autologous mesenchymal stem cells prepared in the invention has the advantages of good treatment effect, convenience in treatment, low cost, etc.

The invention discloses a Kadsurae Caulis-loading I/III type collagen composite scaffold, which is prepared by using bovine source I type collagen, recombinant human source III type collagen, KadsuraeCaulis and PLGA as raw materials. The preparation process comprises: preparation of Kadsurae Caulis-loading PLGA microspheres, preparation of I/III type collagen composite scaffold, loading of Kadsurae Caulis-loading PLGA microspheres, and other steps. According to the present invention, the prepared composite scaffold integrates the characteristics of the I type collagen ribbon fiber structure and the III type collagen reticular fiber structure, further has characteristics of suitable three-dimensional network structure, good biocompatibility, no toxicity, degradability and low immunogenicity, integrates the osteoarthritis treatment effect of Kadsurae Caulis, and is the good medical material for osteoarthritis cartilage defect repair and treatment.

A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibody

Provided is a monoclonal antibody specifically reactive with a C-terminal neo-epitope of PIIINP comprised in a C-terminal amino acid sequence CPTGXQNYSP-COOH (SEQ ID NO: 4) in which X is Gly or Pro, and where the monoclonal antibody does not recognise or bind an elongated version of the C-terminal amino acid sequence CPTGXQNYSPQZ-COOH (SEQ ID NO: 5), in which Z is absent or is one or more amino acids of the sequence of collagen type III. Also provided is a method of immunoassay for detecting in a biological sample the C-terminal neo-epitope of PIIINP generated by N-protease cleavage of intact type III procollagen, by contacting the sample with the monoclonal antibody, and determining the amount of binding of the antibody.